Clinical trials recruiting in Zhangzhou, China

Phase breakdown

Conditions recruiting in Zhangzhou, China

Recruiting trials in Zhangzhou, China

• A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
  NCT07043725 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
  NCT07010263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
  NCT07136792 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
  NCT06471257 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female)
• JS207 Combination Therapy in Triple-negative Breast Cancer
  NCT07045311 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
  NCT07363642 · Phase: Phase 3 · Ages: 12 Years to 80 Years · Sex: All (male and female)
• Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
  NCT07444372 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female)
• TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
  NCT06829784 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-management
  NCT06909773 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
  NCT07139301 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
  NCT07139314 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
  NCT06761027 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Zhangzhou, China?

16 recruiting trials have at least one study site in Zhangzhou, China.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.